IR@PKUHSC  > 北京大学第一临床医学院  > 肿瘤化疗科
学科主题临床医学
Effect of Metformin on Cancer Risk and Treatment Outcome of Prostate Cancer: A Meta-Analysis of Epidemiological Observational Studies
Yu, Hongliang1,2; Yin, Li1,2; Jiang, Xuesong1,2; Sun, Xiujin1,2; Wu, Jing1,2; Tian, Hao1,2; Gao, Xianshu3; He, Xia1,2
刊名PLOS ONE
2014-12-29
DOI10.1371/journal.pone.0116327
9期:12
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
资助者Jiangsu Provincial Natural Science Fund ; "333" Project of Jiangsu Province ; Six Major Talent Peak Project of Jiangsu Province ; Natural Science Foundation of China ; Jiangsu Provincial Natural Science Fund ; "333" Project of Jiangsu Province ; Six Major Talent Peak Project of Jiangsu Province ; Natural Science Foundation of China
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]DIABETIC-PATIENTS ; INCIDENT CANCER ; CLINICAL-TRIALS ; BREAST-CANCER ; SULFONYLUREA ; MORTALITY ; COHORT ; SURVIVAL ; IMPACT ; BIAS
英文摘要

Background: Laboratory studies have shown the anti-tumor effect of metformin on prostate cancer. However, recent epidemiological studies have yielded inconclusive results.

Methods: We searched PubMed database from the inception to May 30 2014 for studies which assessed the effect of metformin use on cancer risk of prostate cancer, biochemical recurrence (BCR) and all-cause mortality of patients with prostate cancer. The pooled results and 95% confidence intervals (CIs) were estimated by random-effect model.

Results: Twenty-one studies were eligible according to the inclusion criteria. Based on the pooled results of available observational studies, metformin use was significantly associated with a decreased cancer risk (14 datasets, 963991 male subjects, odds ratio: 0.91, 95% CI: 0.85-0.97) and BCR (6 datasets, 2953 patients, hazard ratio: 0.81, 95% CI: 0.68-0.98) of prostate cancer. However, the association of metformin use with all-cause mortality of patients with prostate cancer was not significant (5 datasets, 9241 patients, hazard ratio: 0.86, 95% CI: 0.64-1.14).

Conclusion: Results suggest that metformin use appears to be associated with a significant reduction in the cancer risk and BCR of prostate cancer, but not in all-cause mortality of patients with prostate cancer.

语种英语
所属项目编号BK20141018 ; BRA2013292 ; WS-047 ; 30670619 ; 81072017
资助者Jiangsu Provincial Natural Science Fund ; "333" Project of Jiangsu Province ; Six Major Talent Peak Project of Jiangsu Province ; Natural Science Foundation of China ; Jiangsu Provincial Natural Science Fund ; "333" Project of Jiangsu Province ; Six Major Talent Peak Project of Jiangsu Province ; Natural Science Foundation of China
WOS记录号WOS:000347120200112
引用统计
被引频次:26[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60868
专题北京大学第一临床医学院_肿瘤化疗科
作者单位1.Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Dept Radiat Oncol, Nanjing, Jiangsu, Peoples R China
2.Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China
3.Peking Univ, Hosp 1, Dept Radiat Oncol, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Yu, Hongliang,Yin, Li,Jiang, Xuesong,et al. Effect of Metformin on Cancer Risk and Treatment Outcome of Prostate Cancer: A Meta-Analysis of Epidemiological Observational Studies[J]. PLOS ONE,2014,9(12).
APA Yu, Hongliang.,Yin, Li.,Jiang, Xuesong.,Sun, Xiujin.,Wu, Jing.,...&He, Xia.(2014).Effect of Metformin on Cancer Risk and Treatment Outcome of Prostate Cancer: A Meta-Analysis of Epidemiological Observational Studies.PLOS ONE,9(12).
MLA Yu, Hongliang,et al."Effect of Metformin on Cancer Risk and Treatment Outcome of Prostate Cancer: A Meta-Analysis of Epidemiological Observational Studies".PLOS ONE 9.12(2014).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yu, Hongliang]的文章
[Yin, Li]的文章
[Jiang, Xuesong]的文章
百度学术
百度学术中相似的文章
[Yu, Hongliang]的文章
[Yin, Li]的文章
[Jiang, Xuesong]的文章
必应学术
必应学术中相似的文章
[Yu, Hongliang]的文章
[Yin, Li]的文章
[Jiang, Xuesong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。